**Note**

**Antimalarial Phenanthroindolizine Alkaloids from *Ficus septica***

Miwa Kubo,*a Wataru Yatsuzuka,a Shoko Matsushima,a Kenichi Harada,a Yusuke Inoue,b Hisashi Miyamoto,b Makoto Matsumoto,b and Yoshiyasu Fukuyama*a,a

*a Faculty of Pharmaceutical Sciences, Tokushima Bunri University; Tokushima 770–8514, Japan; and
b Microbiological Research Institute, Otsuka Pharmaceutical Co., Ltd.; 463–10 Kagasuno, Kawauti-cho, Tokushima 771–0192, Japan.

Received February 24, 2016; accepted March 7, 2016

During the screening of antimalarial substances, MeOH extract from the twigs of *Ficus septica* was shown to have potent antimalarial activity. Bioassay-guided fractionation of a methanol extract of the twigs of *F. septica* led to the isolation of a new seco-phenanthroindolizine alkaloid and three known phenanthroindolizine alkaloids. Their structures were elucidated on the basis of NMR analysis. All isolated compounds were tested against *Plasmodium falciparum*. Compounds 2–4 displayed antimalarial activity against the 3D7 strain of *P. falciparum* with IC50 values 0.028–0.42 µM, whereas a new compound 1 exhibited a moderate antimalarial activity.

**Key words**  *Ficus septica*; phenanthroindolizine; alkaloid; antimalarial activity

Malaria is caused by *Plasmodium* parasites. The parasites are spread to people through the bites of infected female *Anopheles* mosquitoes, called "malaria vectors." There are five parasite species that cause malaria in humans. *P. falciparum* remains the most dangerous species and causes the most lethal form of malaria. In 2015, about 3.2 billion people, almost half of the world's population, were at risk of malaria. According to the latest WHO report, malaria infections impacted an estimated 214 million people across 97 different countries, resulting in an estimated 438000 death. Early diagnosis and treatment of malaria reduces disease and prevents death. The best available treatment, particularly for *P. falciparum* malaria, is artemisinin based combination therapy (ACT). However, the incidence of malaria is now increasing because of the appearance of multi-drug resistant *P. falciparum*, therefore new pharmacophore and more effective antimalarial drugs are urgently required. Natural products remain important potential sources of new and selective substances for the treatment of malaria.

*Ficus septica* is a small, arboreous, and evergreen plant belonging to the family *Moraceae* that is distributed widely throughout the tropical and subtropical regions of the Western Pacific area. This plant has been used in folk medicine to treat colds, fevers, headaches, gastralgia, and fungal and bacterial diseases and has been reported to contain phenanthroindolizine-type alkaloids, triterpenoids, and phenolic compounds. Among these components, the phenanthroindolizine-type alkaloids have important biological effects, including anti-inflammatory, antitumor, antifungal, and antibacterial activities. In our search for natural products with antimalarial activity, we assayed the anti-*P. falciparum* effects of 250 crude extracts of plants in our laboratory. As a result, we found that a MeOH extract of the twigs of *F. septica* showed a significant *in vitro* antiplasmodial activity on the 3D7 of *P. falciparum* with IC50 value of 2.0 µg/mL. No reports have been published on antimalarial activities of this plant and phenanthroindolizine-type alkaloids. The MeOH extract was suspended in H2O and extracted with chloroform and n-BuOH. The chloroform-soluble portion showed the most potent antimalarial activity. Bioassay-guided fractionation resulted in the isolation of a new seco-phenanthroindolizine-type alkaloid, compound 1, along with three previously known compounds, dehydrotylophorine (2), dehydroantofine (3), and tylophoridicine D (4). In this paper, we report the structures of 1 and antimalarial activities of all four isolated compounds (Fig. 1).

Compound 1, gave the molecular formula, C23H24NO3, as deduced from the high resolution (HR)-FAB-MS at m/z
362.1751 [M]^+ , which suggested the presence of 13 degrees of unsaturation. The 1H- and 13C-NMR data of I (Table 1) indicated the presence of three methylenes [δ_H 2.57 (2H, q, J=7.6 Hz); δ_C 22.8 (C-12), δ_H 3.58 (2H, t, J=7.6 Hz); δ_C 32.9 (C-13), δ_H 4.86 (2H, t, J=7.6 Hz); δ_C 59.7 (C-11)], three methoxy groups [δ_C 3.53, 3.80, 3.84], a 1,4-disubstituted benzene ring [δ_H 6.95 (2H, d, J=8.8 Hz), 7.18 (2H, d, J=8.8 Hz), and a 1,2,4-trisubstituted benzene ring [δ_H 6.73 (2H, d, J=1.6 Hz); δ_C 114.3 (C-1), δ_H 6.98 (d, J=8.6 Hz); δ_C 112.8 (C-4), δ_H 7.00 (dd, J=8.6, 1.6 Hz); δ_C 124.1 (C-4a)], and an aromatic moiety with tetrasubstituents [δ_H 8.04 (s); δ_C 125.5, δ_H 8.82 (s); δ_C 142.0]. These 1H-NMR data of I was similar to those of dehydroantofine (3) except for substituted patterns of two benzene rings A and B in 3. In the case of 3, the two benzene rings corresponding to the rings A and B in I are fused between C-4a and C-4b to form a phenanthrene ring, whereas the NMR data and the molecular formula of I showed that two benzene rings A and B in I (Fig. 2) are not linked and independent of each other. This disclosed that I should be a 4a,b-seco type of 3. The positions of two phenolic methoxy groups on the aromatic ring A and one methoxy group on the aromatic ring B were determined to be at C-2 and C-3, and C-6, respectively, by heteronuclear multiple bond connectivity (HMBC) and nuclear Overhauser effect (NOE) (H-1/OCH_3-2, H-4/OCH_3-3, and H-7/OCH_3-6). According to the HMBC correlations of H-9/C-11, 8b, and 14a, and H-14/C-13, and 14a and the HMBC correlations of H-11/C-9 and C-13a, H-12/C-13a, and H-13/C-13a, I turned out to have the same trihydroindolizidinium skeleton as that of 3. In addition, the HMBC correlations of H-1/C-14a and H-9/C-8a and NOEY correlations between H-1/H-14, H-14/H-13 and H-8/H-9, H-9/H-11 suggested that the two benzene rings A and B were located at the C-14a and C-8b positions, respectively. Hence, compound I was assigned as 4a,b-seco-dehydroantofine. Compound I has been reported as a synthetic substance, but it is the first report on isolation from natural plant extracts.

All isolated compounds 1–4 were evaluated for in vitro antimalarial activity against a chloroquine-sensitive strain (3D7) of *P. falciparum* by the modified plasmodium lactate dehydrogenase (pLDH) method, and were tested for cytotoxicity against mouse fibroblast cells L929. Chloroquine, tafenoquine, and artemisinin were used as the reference drugs in all experiments. The in vitro antimalarial activities of these compounds, as indicated by their IC_{50} values, are summarized in Table 2. All isolated compounds showed antimalarial activity against the 3D7 *P. falciparum* strains. Compound 1 showed moderate antimalarial activity with IC_{50} 4.0 µM. Compound 2 also showed toxicity against L929 cells (IC_{50} 8.2 µM), demonstrating low selectivity for the malaria parasite. However, both 3 and 4 showed potent antimalarial activities comparative to those of artemisinin and chloroquine, but were inactive against L929, which displayed a selectivity index of >966. Therefore, cytotoxicity was not considered to be an issue for 3 and 4. Especially, compound 3 exhibited relatively strong activity against chloroquine-sensitive strain of *P. falciparum* and was about 2000-fold selective toward *P. falciparum* in comparison to its activity against L929 cells.

In conclusion, we investigated the MeOH extract of the twigs of *Ficus septica* that exhibited potent antimalarial activity

---

### Table 1. 1H-(500 MHz) and 13C-(125 MHz) NMR Spectral Data of I (CD_3OD)

| Position | δ_C | δ_H |
|----------|-----|-----|
| 1        | 114.3 | 6.73 (d, J=1.6 Hz) |
| 2        | 150.3 |
| 3        | 152.4 |
| 4        | 112.8 | 6.98 (d, J=8.6 Hz) |
| 4a       | 124.1 | 7.00 (dd, J=8.6, 1.6 Hz) |
| 4b       | 132.2 | 7.18 (d, J=8.8 Hz) |
| 5        | 115.5 | 6.95 (d, J=8.8 Hz) |
| 6        | 161.9 |
| 7        | 115.5 | 6.95 (d, J=8.8 Hz) |
| 8        | 132.2 | 7.18 (d, J=8.8 Hz) |
| 8a       | 128.1 |
| 8b       | 139.1 |
| 9        | 142.0 | 8.82 (s) |
| 11       | 59.7  | 4.86 (2H, t, J=7.6 Hz) |
| 12       | 22.8  | 2.57 (2H, quin, J=7.6 Hz) |
| 13       | 32.9  | 3.58 (2H, t, J=7.6 Hz) |
| 13a      | 157.7 |
| 14       | 125.5 | 8.04 (s) |
| 14a      | 157.9 |
| 14b      | 129.5 |
| OCH_3-2  | 56.2  | 3.53 (3H, s) |
| OCH_3-3  | 56.4  | 3.80 (3H, s) |
| OCH_3-6  | 55.9  | 3.84 (3H, s) |

---

### Table 2. Antimalarial and Cytotoxic Activity of Compounds 1–4

| Compound | P.f. 3D7 IC_{50} (µM) | L929 IC_{50} (µM) | SI_{L929/3D7} |
|----------|------------------------|------------------|---------------|
| 1        | 4.0                    | >56              | >14           |
| 2        | 0.42                   | 8.2              | 19.5          |
| 3        | 0.028                  | >55              | >1964         |
| 4        | 0.058                  | >56              | >966          |
| Artemisinin | 0.025                | N.T.            | —             |
| Chloroquine | 0.036                | N.T.            | —             |
| Tafenoquine | 0.025                | N.T.            | —             |

* a) *Plasmodium falciparum* 3D7 strain. b) Selective index. c) Positive control. d) Not tested.
ity, resulting in the isolation of a new seco-phenanthroindolizine alkaloid 1 and known phenanthroindolizine alkaloids 2–4. Compounds 3 and 4 showed a strong growth inhibiting activity on malaria plasmoidium. These have superior antimalarial activity and highly selective toxicity on P. falciparum.

To the best of our knowledge, antimalarial activity of the phenanthroindolizine alkaloid has not been investigated. These results suggest that the phenanthroindolizine alkaloid may be a therapeutic lead of the new pharmacophore of antimalarial drugs.

**Experimental**

**General Procedure** The NMR experiments were performed on a Varian 500 MHz NMR spectrometer. Chemical shifts are given as δ (ppm) and deuterated solvent peaks as references for 1H- and 13C-NMR spectra. HR-FAB-MS was taken on a MStation JMS-700. Silica gel column chromatography (CC) was carried out on Wako C-300, Silica gel 60N (Kanto), and Sephadex LH-20. HPLC was performed on a JASCO PU-1580 pump equipped with a JASCO UV-1575 detector, and all peaks were detected at 254 nm. TLC was carried out with silica gel 60F 254 and PR-18 F254 plates.

**Plant Material** The twigs of Ficus septica were collected on Yaeyama Island, Japan and a voucher specimen (745TW) was deposited at the Institute of Pharmacognosy, Tokushima Bunri University.

**Extraction and Isolation** The twigs of F. septica (1.5 kg) were powdered and extracted with MeOH (5 L) at room temperature for one month to give 37 g of crude extract, followed by solvent removal. The MeOH extract (17.6 g) was suspended in H2O (200 mL) and extracted with chloroform and n-BuOH. The chloroform-soluble portion was subjected to silica gel column chromatography using the stepwise solvent system of chloroform–methanol (100 : 0) to yield 18 fractions (1–18). Active fraction 18 (98.4 mg) was chromatographed on a Sephadex LH-20 column eluted with methanol–chloroform (2 : 3) to yield 5 fractions (19–23). Fraction 22 (46.3 mg) was purified by reversed-phase HPLC (Cosmosil 5C18-AR ii, 46.3 mg) was purified by reversed-phase HPLC (Cosmosil 5C18-AR ii, 10×250 mm, flow rate 0.3 mL/min) eluted with MeOH–H2O (60:40) containing 3% trifluoroacetic acid (TFA) to give 1 (8.8 mg), 2 (5.8 mg), 3 (8.8 mg), and 4 (3.0 mg).

**Antiplasmodial Assay** RPMI-1640 was supplemented with 25 μM N-(2-hydroxyethyl)piperazine-N’-2-ethanesulfonic acid (HEPES), 50 μg/mL hypoxanthine, 0.4% glucose and 5 μg/mL gentamicin. NCTC-135 and Iscove’s modified Dulbecco’s medium (IMDM) were supplemented with sodium bicarbonate. These media were mixed in the ratio of 2:1:1 (RPMI-1640: NCTC-135:IMDM) to prepare reference nutrient intakes (RNI) incomplete medium. In addition, the medium was supplemented with heat inactivated 2.5% human serum and 1.1% Albumax II to make RNI complete medium. Plasmodium falciparum (3D7, strain) was routinely cultured at 37°C under reduced-oxygen condition (5% CO2 and 5% O2), in RNI complete medium supplemented with human erythrocytes to achieve a 3% hematocrit. Compounds were dissolved and diluted in dimethyl sulfoxide (DMSO), and tested in triplicate. P. falciparum culture was prepared at 2% hematocrit and 0.5% parasitemia, and was added to diluted compounds so that 0.5% DMSO in 96-well micro titer plate. Test plates were incubated at 37°C under reduced-oxygen condition for 3 d. Anti-plasmodial activity was analyzed by the modified pLDH method of Makler et al. Briefly, 50 μL of Malstat reagent was dispensed into new micro titer plate. Ten microliters of P. falciparum culture were transferred into the plate, followed by 10 μL of nitro blue tetrazolium (NBT) (0.1%)–polysulfonate (PES) (0.005%) mixture was added. After 2 h, absorbance was read at 650 nm using microplate reader. Artemisinin was used as positive controls, while DMSO was the negative (vehicle) control.

**Cytotoxicity Assay** For evaluation of cytotoxicity, L929 cells were cultured in D-MEM was supplemented with FBS at 37°C, 5% CO2. L929 cultures were prepared at 2×104 cells/mL and were added to diluted compounds so that 1% DMSO in 96-well micro titer plate. The plates were incubated at 37°C for 2 d. Cytotoxicity was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Ten microliters of MTT solution (2.5 mg/mL) were added to 100 μL of L929 cultures. After 4 h, absorbance was read the plate that MTT formazan were dissolved in DMSO at 650 nm using microplate reader.

**Acknowledgments** We thank Dr. Masami Tanaka and Dr. Yasuko Okamoto (TBU) for measuring the NMR spectroscopic and mass spectrometric data. This work was supported by MEXT/JSPS KAKENHI Grant Number (15K08012) and a Grant from JST (AS251Z0137Q).

**Conflict of Interest** The authors declare no conflict of interest.

**References**

1. World Health Organization, “Fact Sheet on the World Malaria Report 2015,” WHO Press, Geneva, Switzerland, 2015.
2. World Health Organization, “WHO Guidelines for the treatment of malaria,” 3rd ed., WHO Press, Geneva, Switzerland, 2015.
3. Weekly Asahi Encyclopedia, “The World of Plants,” Vol. 89, The Asahi Shimbun, Osaka, 1995.
4. Holdsworth D. K., Hurley C. L., Rayner S. E., O. J. Crude Drug Res., 18, 131–139 (1980).
5. Holdsworth D., Lacanienta E., O. J. Crude Drug Res., 19, 155–167 (1981).
6. Holdsworth D., Damas K., Int. Crude Drug Res., 24, 217–225 (1986).
7. Baumgartner B., Erdelmeier C. A. J., Wright A. D., Rali T., Sticher O., Phytochemistry, 29, 3327–3330 (1990).
8. Wu P.-L., Rao K. V., Su C.-H., Kuoh S.-S., Wu T.-S., Heterocycles, 57, 2401–2408 (2002).
9. Damu A. G., Kuo P.-C., Shi L.-S., Li S.-Y., Kuoh C.-S., Wu P.-L., Wu T.-S., J. Nat. Prod., 68, 1071–1075 (2005).
10. Ueda J., Takagi M., Shim-ya K., J. Nat. Prod., 75, 2181–2183 (2008).
11. Damu A. G., Kuo P.-C., Shi L.-S., Li C.-Y., Su C.-C., Wu T.-S., Planta Med., 75, 1152–1156 (2009).
12. Anda M., Han Y., Nomura T., Heterocycles, 41, 2761–2768 (1995).
13. Langenberger G., Priege V., Martin K., Belonias B., Sauerborn J., Agrofar. Syst., 76, 173–194 (2009).
14. Staan K., Christensen J., Lemmich E., Duus J. O., Olsen C. E., Ethnopharmacol., 41, 395–413 (2008).
15. Dubois D., Christensen J., Lemmich E., Duus J. O., Olsen C. E., Ethnopharmacol., 41, 395–413 (2008).
16. World Health Organization, “Fact Sheet on the World Malaria Report 2015,” WHO Press, Geneva, Switzerland, 2015.
17. Lansky E. P., Paavilainen H. M., Pawlus A. D., Newman R. A., J. Nat. Prod., 70, 1071–1075 (2007).
18. Damu A. G., Kuo P.-C., Shi L.-S., Li S.-Y., Kuoh C.-S., Wu P.-L., Wu T.-S., J. Nat. Prod., 68, 1071–1075 (2005).
19. Ueda J., Takagi M., Shim-ya K., J. Nat. Prod., 75, 2181–2183 (2008).
20. Damu A. G., Kuo P.-C., Shi L.-S., Li C.-Y., Su C.-C., Wu T.-S., Planta Med., 75, 1152–1156 (2009).
21. Anda M., Han Y., Nomura T., Heterocycles, 41, 2761–2768 (1995).
22. Lansky E. P., Paavilainen H. M., Pawlus A. D., Newman R. A., J. Ethnopharmacol., 119, 195–213 (2008).
23. Langenberger G., Priege V., Martin K., Belonias B., Sauerborn J., Agrofar. Syst., 76, 173–194 (2009).
24. Staan K., Christensen J., Lemmich E., Duus J. O., Olsen C. E., Ethnopharmacol., 41, 395–413 (2008).
16) Jaroszewski J. W., J. Nat. Prod., 63, 1584–1586 (2000).
17) Li Z., Zhong J., Huang R., Synthesis, 16, 2365–2378 (2001).
18) Yang C.-W., Chuang T.-H., Wu P.-L., Huang W.-H., Lee S.-J., Biochem. Biophys. Res. Commun., 354, 942–948 (2007).
19) Cave A., Leboeuf M., Moskowitz H., Ranaivo A., Bick I. R. C., Sinchai W., Nieto M., Sevenet T., Cabalion P., Aust. J. Chem., 42, 2243–2263 (1989).
20) Marco A. C., Frank R., J. Am. Chem. Soc., 118, 12082–12089 (1996).
21) Makler M. T., Hinrichs D. J., Am. J. Trop. Med. Hyg., 48, 205–210 (1993).
22) Makler M. T., Ries J. M., Williams J. A., Bancroft J. E., Piper R. C., Gibbins B. L., Hinrichs D. J., Am. J. Trop. Med. Hyg., 48, 739–741 (1993).
23) Tanabe K., Waki S., Kojima S., Kita K., “Laboratory Manual for Malaria,” Konsai Press, Japan, 2000, pp. 69–72.